Development of selective agonists and antagonists of P2Y receptors View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2008-07-04

AUTHORS

Kenneth A. Jacobson, Andrei A. Ivanov, Sonia de Castro, T. Kendall Harden, Hyojin Ko

ABSTRACT

Although elucidation of the medicinal chemistry of agonists and antagonists of the P2Y receptors has lagged behind that of many other members of group A G protein-coupled receptors, detailed qualitative and quantitative structure-activity relationships (SARs) were recently constructed for several of the subtypes. Agonists selective for P2Y(1), P2Y(2), and P2Y(6) receptors and nucleotide antagonists selective for P2Y(1) and P2Y(12) receptors are now known. Selective nonnucleotide antagonists were reported for P2Y(1), P2Y(2), P2Y(6), P2Y(11), P2Y(12), and P2Y(13) receptors. At the P2Y(1) and P2Y(12) receptors, nucleotide agonists (5'-diphosphate derivatives) were converted into antagonists of nanomolar affinity by altering the phosphate moieties, with a focus particularly on the ribose conformation and substitution pattern. Nucleotide analogues with conformationally constrained ribose-like rings were introduced as selective receptor probes for P2Y(1) and P2Y(6) receptors. Screening chemically diverse compound libraries has begun to yield new lead compounds for the development of P2Y receptor antagonists, such as competitive P2Y(12) receptor antagonists with antithrombotic activity. Selective agonists for the P2Y(4), P2Y(11), and P2Y(13) receptors and selective antagonists for P2Y(4) and P2Y(14) receptors have not yet been identified. The P2Y(14) receptor appears to be the most restrictive of the class with respect to modification of the nucleobase, ribose, and phosphate moieties. The continuing process of ligand design for the P2Y receptors will aid in the identification of new clinical targets. More... »

PAGES

75-89

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11302-008-9106-2

DOI

http://dx.doi.org/10.1007/s11302-008-9106-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1035237157

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18600475


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 8A, Rm. B1A-19, Bethesda, MD USA", 
          "id": "http://www.grid.ac/institutes/grid.419635.c", 
          "name": [
            "Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 8A, Rm. B1A-19, Bethesda, MD USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jacobson", 
        "givenName": "Kenneth A.", 
        "id": "sg:person.014152227617.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014152227617.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 8A, Rm. B1A-19, Bethesda, MD USA", 
          "id": "http://www.grid.ac/institutes/grid.419635.c", 
          "name": [
            "Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 8A, Rm. B1A-19, Bethesda, MD USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ivanov", 
        "givenName": "Andrei A.", 
        "id": "sg:person.0775335614.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775335614.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 8A, Rm. B1A-19, Bethesda, MD USA", 
          "id": "http://www.grid.ac/institutes/grid.419635.c", 
          "name": [
            "Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 8A, Rm. B1A-19, Bethesda, MD USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Castro", 
        "givenName": "Sonia", 
        "id": "sg:person.01141223614.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141223614.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27599 USA", 
          "id": "http://www.grid.ac/institutes/grid.10698.36", 
          "name": [
            "Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27599 USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harden", 
        "givenName": "T. Kendall", 
        "id": "sg:person.01160657706.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160657706.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 8A, Rm. B1A-19, Bethesda, MD USA", 
          "id": "http://www.grid.ac/institutes/grid.419635.c", 
          "name": [
            "Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 8A, Rm. B1A-19, Bethesda, MD USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ko", 
        "givenName": "Hyojin", 
        "id": "sg:person.01261700672.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261700672.49"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11302-005-5302-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030665687", 
          "https://doi.org/10.1007/s11302-005-5302-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11302-005-0648-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026073947", 
          "https://doi.org/10.1007/s11302-005-0648-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10822-006-9054-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040736614", 
          "https://doi.org/10.1007/s10822-006-9054-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm1188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038649057", 
          "https://doi.org/10.1038/nm1188"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35051599", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041470828", 
          "https://doi.org/10.1038/35051599"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1007168215748", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026325820", 
          "https://doi.org/10.1023/a:1007168215748"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-07-04", 
    "datePublishedReg": "2008-07-04", 
    "description": "Although elucidation of the medicinal chemistry of agonists and antagonists of the P2Y receptors has lagged behind that of many other members of group A G protein-coupled receptors, detailed qualitative and quantitative structure-activity relationships (SARs) were recently constructed for several of the subtypes. Agonists selective for P2Y(1), P2Y(2), and P2Y(6) receptors and nucleotide antagonists selective for P2Y(1) and P2Y(12) receptors are now known. Selective nonnucleotide antagonists were reported for P2Y(1), P2Y(2), P2Y(6), P2Y(11), P2Y(12), and P2Y(13) receptors. At the P2Y(1) and P2Y(12) receptors, nucleotide agonists (5'-diphosphate derivatives) were converted into antagonists of nanomolar affinity by altering the phosphate moieties, with a focus particularly on the ribose conformation and substitution pattern. Nucleotide analogues with conformationally constrained ribose-like rings were introduced as selective receptor probes for P2Y(1) and P2Y(6) receptors. Screening chemically diverse compound libraries has begun to yield new lead compounds for the development of P2Y receptor antagonists, such as competitive P2Y(12) receptor antagonists with antithrombotic activity. Selective agonists for the P2Y(4), P2Y(11), and P2Y(13) receptors and selective antagonists for P2Y(4) and P2Y(14) receptors have not yet been identified. The P2Y(14) receptor appears to be the most restrictive of the class with respect to modification of the nucleobase, ribose, and phosphate moieties. The continuing process of ligand design for the P2Y receptors will aid in the identification of new clinical targets.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11302-008-9106-2", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2716263", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2724771", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1035517", 
        "issn": [
          "1573-9538", 
          "1573-9546"
        ], 
        "name": "Purinergic Signalling", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "keywords": [
      "structure-activity relationships", 
      "diverse compound libraries", 
      "quantitative structure-activity relationships", 
      "new lead compounds", 
      "medicinal chemistry", 
      "ligand design", 
      "compound libraries", 
      "substitution pattern", 
      "lead compounds", 
      "ribose conformation", 
      "phosphate moiety", 
      "moiety", 
      "nucleotide antagonists", 
      "nanomolar affinity", 
      "receptor probe", 
      "chemistry", 
      "nucleobase", 
      "compounds", 
      "conformation", 
      "new clinical target", 
      "elucidation", 
      "ring", 
      "ribose", 
      "analogues", 
      "antithrombotic activity", 
      "affinity", 
      "probe", 
      "modification", 
      "selective agonist", 
      "protein-coupled receptors", 
      "activity", 
      "process", 
      "group", 
      "class", 
      "library", 
      "development", 
      "identification", 
      "respect", 
      "target", 
      "clinical targets", 
      "design", 
      "selective antagonist", 
      "P2Y receptor antagonists", 
      "receptors", 
      "agonists", 
      "relationship", 
      "antagonist", 
      "focus", 
      "patterns", 
      "receptor antagonist", 
      "P2Y receptors", 
      "members", 
      "subtypes", 
      "members of groups", 
      "Selective nonnucleotide antagonists", 
      "nonnucleotide antagonists", 
      "ribose-like rings", 
      "selective receptor probes"
    ], 
    "name": "Development of selective agonists and antagonists of P2Y receptors", 
    "pagination": "75-89", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1035237157"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11302-008-9106-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18600475"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11302-008-9106-2", 
      "https://app.dimensions.ai/details/publication/pub.1035237157"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_470.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11302-008-9106-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11302-008-9106-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11302-008-9106-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11302-008-9106-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11302-008-9106-2'


 

This table displays all metadata directly associated to this object as RDF triples.

179 TRIPLES      22 PREDICATES      90 URIs      76 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11302-008-9106-2 schema:about anzsrc-for:06
2 anzsrc-for:0601
3 schema:author N8338de6ce057493b9b178ff3058ada70
4 schema:citation sg:pub.10.1007/s10822-006-9054-2
5 sg:pub.10.1007/s11302-005-0648-2
6 sg:pub.10.1007/s11302-005-5302-5
7 sg:pub.10.1023/a:1007168215748
8 sg:pub.10.1038/35051599
9 sg:pub.10.1038/nm1188
10 schema:datePublished 2008-07-04
11 schema:datePublishedReg 2008-07-04
12 schema:description Although elucidation of the medicinal chemistry of agonists and antagonists of the P2Y receptors has lagged behind that of many other members of group A G protein-coupled receptors, detailed qualitative and quantitative structure-activity relationships (SARs) were recently constructed for several of the subtypes. Agonists selective for P2Y(1), P2Y(2), and P2Y(6) receptors and nucleotide antagonists selective for P2Y(1) and P2Y(12) receptors are now known. Selective nonnucleotide antagonists were reported for P2Y(1), P2Y(2), P2Y(6), P2Y(11), P2Y(12), and P2Y(13) receptors. At the P2Y(1) and P2Y(12) receptors, nucleotide agonists (5'-diphosphate derivatives) were converted into antagonists of nanomolar affinity by altering the phosphate moieties, with a focus particularly on the ribose conformation and substitution pattern. Nucleotide analogues with conformationally constrained ribose-like rings were introduced as selective receptor probes for P2Y(1) and P2Y(6) receptors. Screening chemically diverse compound libraries has begun to yield new lead compounds for the development of P2Y receptor antagonists, such as competitive P2Y(12) receptor antagonists with antithrombotic activity. Selective agonists for the P2Y(4), P2Y(11), and P2Y(13) receptors and selective antagonists for P2Y(4) and P2Y(14) receptors have not yet been identified. The P2Y(14) receptor appears to be the most restrictive of the class with respect to modification of the nucleobase, ribose, and phosphate moieties. The continuing process of ligand design for the P2Y receptors will aid in the identification of new clinical targets.
13 schema:genre article
14 schema:inLanguage en
15 schema:isAccessibleForFree true
16 schema:isPartOf N4e4711d6317144808fbfb3abddf26ecd
17 Nc4a7e14767064d4ab0677b5a6f9e4ca3
18 sg:journal.1035517
19 schema:keywords P2Y receptor antagonists
20 P2Y receptors
21 Selective nonnucleotide antagonists
22 activity
23 affinity
24 agonists
25 analogues
26 antagonist
27 antithrombotic activity
28 chemistry
29 class
30 clinical targets
31 compound libraries
32 compounds
33 conformation
34 design
35 development
36 diverse compound libraries
37 elucidation
38 focus
39 group
40 identification
41 lead compounds
42 library
43 ligand design
44 medicinal chemistry
45 members
46 members of groups
47 modification
48 moiety
49 nanomolar affinity
50 new clinical target
51 new lead compounds
52 nonnucleotide antagonists
53 nucleobase
54 nucleotide antagonists
55 patterns
56 phosphate moiety
57 probe
58 process
59 protein-coupled receptors
60 quantitative structure-activity relationships
61 receptor antagonist
62 receptor probe
63 receptors
64 relationship
65 respect
66 ribose
67 ribose conformation
68 ribose-like rings
69 ring
70 selective agonist
71 selective antagonist
72 selective receptor probes
73 structure-activity relationships
74 substitution pattern
75 subtypes
76 target
77 schema:name Development of selective agonists and antagonists of P2Y receptors
78 schema:pagination 75-89
79 schema:productId N424ebf780b05431f8a42f7c5d0ee05c7
80 N79113bc0b3ba45289034189dddb73ef3
81 Nf8a57abe62464dff8f906246d263f085
82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035237157
83 https://doi.org/10.1007/s11302-008-9106-2
84 schema:sdDatePublished 2021-11-01T18:12
85 schema:sdLicense https://scigraph.springernature.com/explorer/license/
86 schema:sdPublisher Nea788fd585a5435a9191153619d9c951
87 schema:url https://doi.org/10.1007/s11302-008-9106-2
88 sgo:license sg:explorer/license/
89 sgo:sdDataset articles
90 rdf:type schema:ScholarlyArticle
91 N0b553fb8c5d94b319dfc0ba1a69b86b3 rdf:first sg:person.01261700672.49
92 rdf:rest rdf:nil
93 N1411dd64152a4e9aa6fd6f2af46f0af9 rdf:first sg:person.01160657706.36
94 rdf:rest N0b553fb8c5d94b319dfc0ba1a69b86b3
95 N424ebf780b05431f8a42f7c5d0ee05c7 schema:name dimensions_id
96 schema:value pub.1035237157
97 rdf:type schema:PropertyValue
98 N4e4711d6317144808fbfb3abddf26ecd schema:issueNumber 1
99 rdf:type schema:PublicationIssue
100 N79113bc0b3ba45289034189dddb73ef3 schema:name pubmed_id
101 schema:value 18600475
102 rdf:type schema:PropertyValue
103 N8338de6ce057493b9b178ff3058ada70 rdf:first sg:person.014152227617.67
104 rdf:rest Nb6c2f1f5b79d49aeaea2ef0c6c63bd36
105 Nb6c2f1f5b79d49aeaea2ef0c6c63bd36 rdf:first sg:person.0775335614.68
106 rdf:rest Nfa78924285ea431ca6bc246302afc920
107 Nc4a7e14767064d4ab0677b5a6f9e4ca3 schema:volumeNumber 5
108 rdf:type schema:PublicationVolume
109 Nea788fd585a5435a9191153619d9c951 schema:name Springer Nature - SN SciGraph project
110 rdf:type schema:Organization
111 Nf8a57abe62464dff8f906246d263f085 schema:name doi
112 schema:value 10.1007/s11302-008-9106-2
113 rdf:type schema:PropertyValue
114 Nfa78924285ea431ca6bc246302afc920 rdf:first sg:person.01141223614.07
115 rdf:rest N1411dd64152a4e9aa6fd6f2af46f0af9
116 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
117 schema:name Biological Sciences
118 rdf:type schema:DefinedTerm
119 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
120 schema:name Biochemistry and Cell Biology
121 rdf:type schema:DefinedTerm
122 sg:grant.2716263 http://pending.schema.org/fundedItem sg:pub.10.1007/s11302-008-9106-2
123 rdf:type schema:MonetaryGrant
124 sg:grant.2724771 http://pending.schema.org/fundedItem sg:pub.10.1007/s11302-008-9106-2
125 rdf:type schema:MonetaryGrant
126 sg:journal.1035517 schema:issn 1573-9538
127 1573-9546
128 schema:name Purinergic Signalling
129 schema:publisher Springer Nature
130 rdf:type schema:Periodical
131 sg:person.01141223614.07 schema:affiliation grid-institutes:grid.419635.c
132 schema:familyName de Castro
133 schema:givenName Sonia
134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141223614.07
135 rdf:type schema:Person
136 sg:person.01160657706.36 schema:affiliation grid-institutes:grid.10698.36
137 schema:familyName Harden
138 schema:givenName T. Kendall
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160657706.36
140 rdf:type schema:Person
141 sg:person.01261700672.49 schema:affiliation grid-institutes:grid.419635.c
142 schema:familyName Ko
143 schema:givenName Hyojin
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261700672.49
145 rdf:type schema:Person
146 sg:person.014152227617.67 schema:affiliation grid-institutes:grid.419635.c
147 schema:familyName Jacobson
148 schema:givenName Kenneth A.
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014152227617.67
150 rdf:type schema:Person
151 sg:person.0775335614.68 schema:affiliation grid-institutes:grid.419635.c
152 schema:familyName Ivanov
153 schema:givenName Andrei A.
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775335614.68
155 rdf:type schema:Person
156 sg:pub.10.1007/s10822-006-9054-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040736614
157 https://doi.org/10.1007/s10822-006-9054-2
158 rdf:type schema:CreativeWork
159 sg:pub.10.1007/s11302-005-0648-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026073947
160 https://doi.org/10.1007/s11302-005-0648-2
161 rdf:type schema:CreativeWork
162 sg:pub.10.1007/s11302-005-5302-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030665687
163 https://doi.org/10.1007/s11302-005-5302-5
164 rdf:type schema:CreativeWork
165 sg:pub.10.1023/a:1007168215748 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026325820
166 https://doi.org/10.1023/a:1007168215748
167 rdf:type schema:CreativeWork
168 sg:pub.10.1038/35051599 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041470828
169 https://doi.org/10.1038/35051599
170 rdf:type schema:CreativeWork
171 sg:pub.10.1038/nm1188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038649057
172 https://doi.org/10.1038/nm1188
173 rdf:type schema:CreativeWork
174 grid-institutes:grid.10698.36 schema:alternateName Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27599 USA
175 schema:name Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27599 USA
176 rdf:type schema:Organization
177 grid-institutes:grid.419635.c schema:alternateName Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 8A, Rm. B1A-19, Bethesda, MD USA
178 schema:name Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 8A, Rm. B1A-19, Bethesda, MD USA
179 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...